Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 4 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; hydrophobic colloidal silica anhydrous; lactose monohydrate - treatment of hypertension. treatment should not be initiated with this combination.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 4 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: hydrophobic colloidal silica anhydrous; lactose monohydrate; magnesium stearate; microcrystalline cellulose - treatment of hypertension. treatment should not be initiated with this combination.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: magnesium stearate; hydrophobic colloidal silica anhydrous; microcrystalline cellulose; lactose monohydrate - the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that idaprex be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of idaprex has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; hydrophobic colloidal silica anhydrous; magnesium stearate; lactose monohydrate - the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that idaprex be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of idaprex has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pyrimethamine, quantity: 25 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; docusate sodium - daraprim in combination with a sulphonamide is effective in the treatment of congenital and acquired infections.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

mcneil healthcare (ireland) ltd - pseudoephedrine hydrochloride, triprolidine hydrochloride - tablets - 60/2.5 milligram - sympathomimetics

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - indapamide hemihydrate, quantity: 0.625 mg; perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; maltodextrin; magnesium stearate; colloidal anhydrous silica; macrogol 6000; lactose monohydrate; colour - treatment of hypertension.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - azathioprine, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; maize starch; purified talc; povidone; hypromellose; microcrystalline cellulose; peg-8 stearate - immunosuppressant antimetabolite: either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - azathioprine, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; microcrystalline cellulose; macrogol 8000; hypromellose; macrogol 400 - azathioprine is used as an immunosuppressant anti-metabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effects may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids.,azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants.,azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: ,? severe rheumatoid arthritis;,? systemic lupus erythematosus;,? dermatomyositis / polymyositis;,? autoimmune chronic active hepatitis;,? pemphigus vulgaris;,? polyarteritis nodosa;,? autoimmune haemolytic anaemia; ,? chronic refractory idiopathic thrombocytopenic purpura.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - azathioprine, quantity: 25 mg - tablet - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - azathioprine is used as an immunosuppressant anti-metabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effects may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids.,azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants.,azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: ,? severe rheumatoid arthritis;,? systemic lupus erythematosus;,? dermatomyositis / polymyositis;,? autoimmune chronic active hepatitis;,? pemphigus vulgaris;,? polyarteritis nodosa;,? autoimmune haemolytic anaemia; ,? chronic refractory idiopathic thrombocytopenic purpura.